An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C (original) (raw)

< Back to Article

Figure 1

Distribution of IL28B rs12979860 genotypes, by response to treatment with pegylated-interferon-α2a plus ribavirin among European American subjects infected with HCV genotype 1, lead-in phase of the HALT-C Trial.

EVR, early virological response; BT, breakthrough; SVR, sustained virological response.

Figure 1

doi: https://doi.org/10.1371/journal.pone.0020904.g001